01/09/2026 Novartis’s remibrutinib significantly reduced relapse rates and demonstrated a favourable safety profile in Ph3 RMS trials. Adicet Bio announced completion of the last patient visit for the planned analysis of prula-cel study in patients with SLE with or without LN. Alumis announced topline results from the Ph2b trail of envudeucitinib in SLE. Novartis’s remibrutinib significantly reduced relapse rates and demonstrated a favourable safety profile in Ph3 RMS trials.